Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression

Transplantation

Volumn 80, Issue 9, 2005, Pages 1233-1243

  Caillard, Sophie ^a,b   Dharnidharka, Vikas ^c   Agodoa, Lawrence ^d   Bohen, Erin ^a,b   Abbott, Kevin ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Immunosuppression; Kidney transplantation; Posttransplant lymphoproliferative disorders; United States Renal Data System

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; INTERLEUKIN 2 RECEPTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; TACROLIMUS;

ADULT; ANAMNESIS; ARTICLE; CONFIDENCE INTERVAL; DEATH; FEMALE; GRAFT REJECTION; GROUPS BY AGE; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY TRANSPLANTATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICARE; NONHODGKIN LYMPHOMA; PATIENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PROCESSING; RECIPIENT; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; IMMUNOSUPPRESSION; INFANT; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; UNITED STATES;

EID: 28544449370     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000179639.98338.39     Document Type: Article

References (32)

1. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1998: 147-158.
2. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4(6): 905-913.
3. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4(2): 222-230.
4. Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA. Post-transplant lymphoproliterative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center. Transplantation 1993; 56(1): 88-96.
5. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323(25): 1723-1728.
6. Penn I. Cancers following cyclosporine therapy. Transplant Proc 1987; 19(1 Pt 3): 2211-2213.
7. Shapiro R, Nalesnik M, McCauley J, et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-baseci immunosuppression. Transplantation 1999; 68(12): 1851-1854.
8. Dharnidharka VR, Sullivan EK, Stablein DM, et al. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001; 71(8): 1063-1068.
9. McLaughlin K, Wajstaub S, Marotta P et al. Increased risk for post-transplant lymphoproliferative disease in recipients of liver transplants with hepatitis C. Liver Transpl 2000; 6(5): 570-574.
10. Buda A, Caforio A, Calabrese F, et al. Lymphoproliferative disorders in heart transplant recipients: role of hepatitis C virus (HCV) and Epstein-Barr virus (EBV) infection. Transpl Int 2000; 13 (Suppl 1): S402-S405.
11. Manez R, Breinig MK, Linden P, et al. Factors associated with the development of post-transplant lymphoproliferative disease (PTLD) in Epstein-Barr virus (EBV)-seronegative adult liver transplant recipients. Transpl Int 1994; 7 (Suppl 1): S235-S237.
12. Swanson SJ, Hypolite IO, Agodoa LY, et al. Effect of donor factors on early graft survival in adult cadaveric renal transplantation. Am J Transplant 2002; 2(1): 68-75.
13. Abbott KC, Yuan CM, Taylor AJ, et al. Early renal insufficiency and hospitalized heart disease after renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003; 14(9): 2358-2365.
14. Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004; 4(1): 87-93.
15. Cherikh WS, Kauffman HM, McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76(9): 1289-1293.
16. Dharnidharka VR, Tejani AH, Ho PL, Harmon WE. Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk Am J Transplant 2002; 2(10): 993-998.
17. Ho M, Miller G, Atchison RW, et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985; 152(5): 876-886
18. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343(7): 481-492.
19. Trofe J, Buell JF, Woodle ES, et al. Recurrence risk after organ transplantation in patients with a history of Hodgkin disease or non-Hodgkin lymphoma. Transplantation 2004; 78(7): 972-977
20. Preiksaitis JK, Diaz-Mitoma F, Mirzayans F, et al. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder. J Infect Dis 1992; 166(5): 986-994.
21. Dharnidharka VR, Stevens G. Risk for post transplant lymphoproliferative disorder after polyclonal antibody induction in kidney transplantation. Pediat Transplant 2005; 9(5): 622-626.
22. Younes BS, McDiarmid SV, Martin MG, et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation 2000; 70(1): 94-99.
23. Penn I. The changing pattern of posttransplant malignancies. Transplant Proc 1991; 23(1 Pt 2): 1101-1103.
24. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351(9103): 623-628.
25. Shah MB, Martin JE, Schroeder TJ, First MR. Evaluation of the safety and tolerability of Neoral and Sandimmune: a meta-analysis. Transplant Proc 1998; 30(5): 1697-1700.
26. Meier-Kriesche HU, Kaplan B. Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograff failure and improved long-term graft survival as compared with sandimmune. Am J Transplant 2002; 2(1): 100-104.
27. Birkeland SA, Andersen HK, Hamilton-Dutoit SJ. Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol. Transplantation 1999; 67(9): 1209-1214.
28. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000; 47(2-3): 85-118.
29. Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996; 10(1 Pt 2): 77-84.
30. Brown VI, Fang J, Alcorn K, et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci USA 2003; 100(25): 15113-15118.
31. Nepomuceno RR, Balatoni CE, Natkunam Y, et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 2003; 63(15): 4472-4480.
32. Morrison VA, DunnDL, Manivel JC, et al. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994; 97(1): 14-24.